Angle, the AIM-listed liquid biopsy company which specialises in circulating tumour cell (CTC) solutions, has announced the results of a clinical study which show that its Parsortix system could be ...

INDEPENDENT STUDY OF OVARIAN CANCER CTCS HARVESTED BY THE PARSORTIX SYSTEM HIGHLIGHTS POTENTIAL TO PREDICT PROGRESSION FREE SURVIVAL FOR DRUG TRIALSThe study investigated 123 metastatic ovarian cancer ...

New Jersey, United States,- The latest report published by MR Accuracy Reports indicates that the Blood Collection Tubes for ...

The global liquid biopsy market is projected to grow significantly, with an estimated value of USD 35.3 billion by 2033, up from USD 10.3 billion in 2023, reflecting a compound annual growth rate ...

The TeloView technology is conducted on the level of the single cell and applicable to liquid biopsy, which positions the technology at the forefront of precision medicine. Emery Pharma specializes in ...

Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories, today ...

The Global Precision Oncology Market signifies a significant transformation in cancer treatment, utilizing advanced ...

An analyst from Goldman Sachs has decided to maintain their Buy rating on Guardant Health, which currently sits at a price ...

Q1 2024 Earnings Call Transcript May 12, 2024 SOPHiA GENETICS SA isn’t one of the 30 most popular stocks among hedge funds at ...

Q1 2024 Earnings Call May 10, 2024 Guardant Health, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end ...

Cancer biopsy tests sold to biopharma companies for use in clinical studies, meanwhile, grew 37% to 8,450. “We also saw continued progress in our EMR integration efforts which streamlines orders and ...